Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfills all inclusion criteria for the PA0012 \[NCT04009499\] study~* Subject is considered reliable and capable of adhering to the DV0004 protocol (eg, able to understand and complete questionnaires, able to use investigational self-injecting device presentations according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator~* Subject is willing to self-inject~Exclusion Criteria:~-Subjects are not permitted to enroll in DV0004 if any of the PA0012 \[NCT04009499\] study exclusion criteria are met

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab-SS (Type: EXPERIMENTAL): Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
- Bimekizumab-AI (Type: EXPERIMENTAL): Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).

Based on this trial design, predict the completion outcome and termination type (if applicable).